The Multiple Myeloma Channel is supported with funding from Sanofi (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | CTCs as a prognostic biomarker in multiple myeloma
Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, discusses the growing clinical relevance of circulating tumour cells (CTCs) in multiple myeloma. He highlights recent evidence supporting CTCs as an independent prognostic biomarker, their ability to improve current risk models, and how standardized cut-offs could facilitate incorporation into future diagnostic and staging pathways. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Well, I think that there was never so much momentum as we have currently regarding the use of CTCs in myeloma circulating tumor cells. The prognostic value has been there for quite some time, but more recently we had some very, very important studies using standardized methods, such as next-generation flow cytometry, large cohorts, some of which treated with a new standard of care, that unequivocally show that CTCs are prognostic...
Well, I think that there was never so much momentum as we have currently regarding the use of CTCs in myeloma circulating tumor cells. The prognostic value has been there for quite some time, but more recently we had some very, very important studies using standardized methods, such as next-generation flow cytometry, large cohorts, some of which treated with a new standard of care, that unequivocally show that CTCs are prognostic. They are independent prognostic factors in multivariate analysis using other risk models. They actually improve the accuracy of all risk models, including the newest IMS-IMWG consensus genomic score. And based on the accumulation of large, large data sets and the development of some important consortia around Europe and even around the world, we now have defined the cut-offs that are ready for clinical implementation. And I’m glad to say that, let’s say, an easy cut-off such as 0.02% CTCs is applicable for the staging not only of smoldering myeloma but also newly diagnosed active myeloma as well as relapsed refractory disease.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
